AXSM

Business Context and Reporting Period

Axsome Therapeutics, Inc. (AXSM) is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) conditions. This Form 10-Q covers the quarterly period ended September 30, 2025. The company currently commercializes three FDA-approved products: Auvelity (major depressive disorder), Sunosi (excessive daytime sleepiness), and Symbravo (acute migraine, launched in June 2025). The company maintains a pipeline of late-stage candidates including AXS-05 (Alzheimer's disease agitation), solriamfetol (ADHD, MDD), AXS-12 (narcolepsy), and AXS-14 (fibromyalgia).

Key Financial Metrics

Note: Debt includes $120.0 million in long-term term loans and $70.0 million in short-term borrowings (revolver) under the Blackstone Loan Agreement. The revolver was repaid in October 2025.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 63% year-over-year in Q3 2025, driven by a 69% increase in Auvelity sales ($136.1M vs $80.4M), a 35% increase in Sunosi sales ($31.6M vs $23.4M), and the initial commercial launch of Symbravo ($2.1M).
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 57% to $150.2 million in Q3 2025, attributed to sales force expansion, direct-to-consumer advertising for Auvelity, and the launch of Symbravo.
• Debt Restructuring: In May 2025, the company entered a new $570 million credit facility with Blackstone, using proceeds to fully repay the prior Hercules Loan Agreement. This resulted in a one-time loss on debt extinguishment of $10.4 million in the nine months ended September 30, 2025.
• Improved Loss Profile: Net loss narrowed by 27% in Q3 2025 compared to the prior year, despite higher operating expenses, due to significant revenue growth.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash resources ($325.3 million) are sufficient to fund operations for at least 12 months. The company expects expenses to increase due to commercialization activities and pipeline development.
• Regulatory Updates:
  • AXS-14 (Fibromyalgia): Received a "Refusal to File" letter from the FDA in June 2025. The company plans to conduct an additional controlled trial with a fixed-dose paradigm and 12-week primary endpoint to address FDA feedback.
  • Symbravo: Approved in January 2025 and commercially launched in June 2025.
• Legal Proceedings: A securities class action lawsuit regarding Symbravo (AXS-07) was preliminarily approved for settlement on October 27, 2025, with a hearing scheduled for February 2026. Multiple shareholder derivative actions remain pending.
• Risk Factors: Key risks include the company's history of losses, dependence on the success of Auvelity, Sunosi, and Symbravo, potential generic competition (Sunosi NCE exclusivity expired June 2024), and the uncertainty of regulatory approvals for pipeline candidates.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the Blackstone Loan Agreement's minimum liquidity covenant of $30.0 million and other restrictive covenants.
• AXS-14 Timeline: Monitor the timeline and design of the additional clinical trial required by the FDA for AXS-14 following the Refusal to File.
• Generic Competition: Assess the impact of settled Paragraph IV litigation for Sunosi (generic launch dates pushed to 2040) and ongoing litigation for other products.
• Reimbursement Trends: Review the impact of the Inflation Reduction Act (IRA) and Medicare Part D redesign on net sales and rebate accruals, particularly for Auvelity and Sunosi.
• Legal Settlement: Confirm the final terms and financial impact of the securities class action settlement regarding Symbravo.